More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control ...

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor ...

More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...

Southampton PhD student Lara Graham’s immunotherapy research has taken on new meaning after it helped her mother’s cancer ...

Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies ...

The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number ...

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31 ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

Doctors warn that prolonged sitting can quietly increase cancer risk by triggering high insulin levels, chronic inflammation, ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...